Felix Hilpert

5PUBLICATIONS
82CO-AUTHORS
Cancer geneticsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jun 12, 2026
Constitutional BRCA1 Promoter Methylation in Patients With Ovarian Cancer: Results of the Observational AGO-TR1 Study.

|Nov 03, 2025
Multiomic Factor Analysis for Pathologic Complete Response after Pembrolizumab + Trastuzumab + Pertuzumab in HER2-Enriched Early Breast Cancer: WSG-Keyriched-1 Trial.

Monika Graeser, Oleg Gluz, Peter Schmid

|Aug 15, 2023
Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer.

Rachel N Grisham, Ignace Vergote, Susana Banerjee

|Nov 04, 2022
Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial.

Jacobus Pfisterer, Florence Joly, Gunnar Kristensen

|Aug 24, 2022
Bevacizumab May Differentially Improve Prognosis of Advanced Ovarian Cancer Patients with Low Expression of VEGF-A165b, an Antiangiogenic VEGF-A Splice Variant.

Pauline Wimberger, Mara Julia Gerber, Jacobus Pfisterer

Pageof 1

Frequent Collaborators

3 joint publications

Jalid Sehouli

2 joint publications

Pauline Wimberger

2 joint publications

Gunnar Kristensen

2 joint publications

Jacobus Pfisterer